Trials / Not Yet Recruiting
Not Yet RecruitingNCT07479485
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Lepu Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG006A | Administrated intravenously |
| DRUG | MRG006A | Administrated intravenously |
| DRUG | MRG006A | Administrated intravenously |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2029-04-01
- First posted
- 2026-03-18
- Last updated
- 2026-03-18
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07479485. Inclusion in this directory is not an endorsement.